eISSN: 1994-4624 / ISSN: 1813-176x
Register
Login
International Journal of Molecular Medicine and Advance Sciences
2005, Volume 1, Issue 4 : 382-391 doi: ijmmas.2005.382.391
Research Article
Reactive Oxidant Species Augment Complement Function in Human Blood Independently of Classical and MBL-Pathways
Published
Dec. 30, 2005
Abstract

Recent evidence suggests that complement plays an important role in the pathogenesis of ischaemia-reperfusion injury and that this may be mediated by reactive oxidant species (ROS). However, it is not clear how individual complement pathways could be affected by ROS. In this study purified C3 and C4 proteins were subjected to a 30 min treatment with ROS generators at 37?C: 1mM authentic peroxynitrite (ONOO-), 10 ?M/10 ?M xanthine/xanthine oxidase mixtures to generate O2- and100 ?M H2O2. We also studied the effect of ROS on complement activation in normal human serum and mannan binding lectin (MBL) deficient serums. In addition, normal human blood was taken from healthy volunteers treated with ROS during 30 min extracorporeal circulation. Sensitive ELISA assays were used to determine the effect of ROS on complement reactivity respectively and whether this related to haemolytic activities. Blood treated with the competitive ligand for MBL binding, N-acetyl-D-glucosamine (GlcNAc=100mM) and untreated blood were used as controls. There was a concentration-dependent modification of protein residues by ROS and that ROS treatment of normal and MBL deficient serums inhibited C4 deposition originating from both MBL and classical pathways and interestingly this was associated with an increased haemolytic activity. The results may suggest that ROS plays an important role in regulating complement activation independently of the classical and MBL pathways and that increased activities may be attributable to a direct effect on the alternate pathway.

Keywords
License
Copyright (c) International Journal of Molecular Medicine and Advance Sciences
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
Int. J. Mol. Med. Adv. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Recommended Articles
Community-Based Health Programs and Their Effectiveness: Evaluating Impacts on Population Health Outcomes
13-19
Personalized Healthcare Using Genomic Data: Advancing Precision Medicine Through Genomic Innovation
51-55
Mental Health Awareness and Help-Seeking Behavior: A Comprehensive Study of Knowledge, Attitudes, Barriers, and Interventions
7-12
Clinical Efficacy of Drug-Eluting Stents Among Hypertensive Patients
41-45
International Journal of Molecular Medicine and Advance Sciences
+447480266638
+447480266638
support@ijmmas.com
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license. Open Access Publication.
Copyright © ©International Journal of Molecular Medicine and Advance Sciences. All rights reserved.